Radioactive tracer trial aims to supercharge cancer drugs
NCT ID NCT07197671
Summary
This early-stage study is testing a new radioactive imaging agent called Y-NM600 in people with advanced cancer that has spread. The main goals are to find a safe dose and see if this agent can help make standard immunotherapy drugs work better. Up to 60 participants who are already receiving anti-PD-1 or anti-PD-L1 therapy will be enrolled for up to 9 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.